nsc 65346 has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, RP; Cai, Y; Eaton, BP; Kocher, GA; Kuhn, JH; Liang, J; Murphy, MJ; Postnikova, EN; Smith, CO; Smith, HC; Yu, S; Zhou, H | 1 |
| Bennett, RP; Jessen, HJ; Kaiser, SM; Ripp, A; Salter, JD; Smith, HC; Yoluç, Y | 1 |
2 other study(ies) available for nsc 65346 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COVID-19; Female; Humans; Male; Mice; Pyrimidine Nucleosides; SARS-CoV-2; Vero Cells | 2022 |
Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
Topics: Antiviral Agents; COVID-19; Humans; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2 | 2023 |